{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:14:50Z","timestamp":1792451690706,"version":"4.5.0"},"reference-count":89,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Pulmonary hypertension associated with interstitial lung disease (ILD-PH) frequently complicates the course of patients with fibrotic ILD. In this narrative review, the authors assess current diagnostic tools and management considerations in ILD-PH patients. ILD-PH is associated with increased morbidity and mortality and may be suggested by the presence of symptoms out of proportion to the extent of the ILD. There are other clues to the presence of PH in the context of ILD including the need for supplemental oxygen, a reduced DLCO especially if accompanied by a disproportionately higher forced vital capacity, imaging demonstrating an enlarged pulmonary artery or a dilated right ventricle, or objective evidence of a reduced exercise capacity. While echocardiography is one screening tool, right heart catheterization remains the gold standard for the diagnosis of PH. When appropriate, treatment with inhaled treprostinil, or possibly other pulmonary vasodilators, may be indicated.<\/jats:p>","DOI":"10.3390\/jcm14062029","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T06:36:23Z","timestamp":1742193383000},"page":"2029","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Review of the Diagnosis and Management of Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH)"],"prefix":"10.3390","volume":"14","author":[{"given":"Zein","family":"Kattih","sequence":"first","affiliation":[{"name":"Advanced Lung Disease and Transplant Program, Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA 22042, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Cheol","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambhu","family":"Aryal","sequence":"additional","affiliation":[{"name":"Advanced Lung Disease and Transplant Program, Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA 22042, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Nathan","sequence":"additional","affiliation":[{"name":"Advanced Lung Disease and Transplant Program, Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA 22042, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2401324","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1183\/13993003.01200-2024","article-title":"Pulmonary hypertension associated with lung diseases","volume":"64","author":"Shlobin","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1801914","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/thorax-2023-220179","article-title":"Mild elevation of pulmonary vascular resistance predicts mortality regardless of mean pulmonary artery pressure in mild interstitial lung disease","volume":"79","author":"Sato","year":"2024","journal-title":"Thorax"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"00630-2021","DOI":"10.1183\/23120541.00630-2021","article-title":"The prevalence and burden of interstitial lung diseases in the USA","volume":"8","author":"Jeganathan","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2045894021999960","DOI":"10.1177\/2045894021999960","article-title":"Impact of the new definition for pulmonary hypertension in patients with lung disease: An analysis of the United Network for Organ Sharing database","volume":"11","author":"Nathan","year":"2021","journal-title":"Pulm. Circ."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.chest.2024.04.025","article-title":"Pulmonary Hypertension in Interstitial Lung Disease: A Systematic Review and Meta-Analysis","volume":"166","author":"Ang","year":"2024","journal-title":"Chest"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e12127","DOI":"10.1002\/pul2.12127","article-title":"Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute\u2019s innovative drug development initiative-Group 3 pulmonary hypertension","volume":"12","author":"Nikkho","year":"2022","journal-title":"Pulm. Circ."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1183\/09031936.00107206","article-title":"Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant","volume":"30","author":"Shorr","year":"2007","journal-title":"Eur. Respir. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000114246","article-title":"Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"76","author":"Nathan","year":"2008","journal-title":"Respiration"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.healun.2009.07.025","article-title":"Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia","volume":"29","author":"Todd","year":"2010","journal-title":"J. Heart Lung Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1183\/13993003.01537-2014","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_14","first-page":"2027","article-title":"Spectrum of interstitial lung diseases and their association with pulmonary hypertension","volume":"92","author":"Tyagi","year":"2021","journal-title":"Monaldi Arch. Chest Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/art.40862","article-title":"Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis","volume":"71","author":"Young","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.30077","article-title":"Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease","volume":"63","author":"Cottin","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1800545","DOI":"10.1183\/13993003.00545-2018","article-title":"Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia","volume":"52","author":"King","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1183\/09031936.05.00021005","article-title":"Combined pulmonary fibrosis and emphysema: A distinct underrecognised entity","volume":"26","author":"Cottin","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1183\/09031936.00010414","article-title":"A haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis","volume":"44","author":"Oliveira","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.3899\/jrheum.101243","article-title":"Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline characteristics and description of study population","volume":"38","author":"Hinchcliff","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: The DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijcard.2007.04.084","article-title":"Pulmonary hypertension in rheumatoid arthritis-relation with the duration of the disease","volume":"127","author":"Udayakumar","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00296-012-2659-y","article-title":"Pulmonary hypertension in rheumatic diseases: Epidemiology and pathogenesis","volume":"33","author":"Shahane","year":"2013","journal-title":"Rheumatol. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4564531","DOI":"10.1155\/2016\/4564531","article-title":"SAPHIRE: Stress and Pulmonary Hypertension in Rheumatoid Evaluation-A Prevalence Study","volume":"2016","author":"Reeves","year":"2016","journal-title":"Int. J. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1164\/rccm.202206-1041ST","article-title":"Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS\/ERS\/JRS\/ALAT Research Statement","volume":"206","author":"Cottin","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2300127","DOI":"10.1183\/13993003.00127-2023","article-title":"Mortality surrogates in combined pulmonary fibrosis and emphysema","volume":"63","author":"Zhao","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1378\/chest.129.3.746","article-title":"Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis","volume":"129","author":"Lettieri","year":"2006","journal-title":"Chest"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2045894018775056","DOI":"10.1177\/2045894018775056","article-title":"Pulmonary hypertension in chronic lung diseases: Comparison to other pulmonary hypertension groups","volume":"8","author":"Chebib","year":"2018","journal-title":"Pulm. Circ."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Alhamad, E.H., Cal, J.G., Alrajhi, N.N., and Alharbi, W.M. (2020). Predictors of Mortality in Patients with Interstitial Lung Disease-Associated Pulmonary Hypertension. J. Clin. Med., 9.","DOI":"10.3390\/jcm9123828"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e12213","DOI":"10.1002\/pul2.12213","article-title":"Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute\u2019s Innovative Drug Development Initiative\u2014Group 3 Pulmonary Hypertension","volume":"13","author":"Piccari","year":"2023","journal-title":"Pulm. Circ."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1164\/rccm.201706-1215OC","article-title":"Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality","volume":"197","author":"Douschan","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/MCP.0000000000000790","article-title":"Pulmonary hypertension in interstitial lung disease: Screening, diagnosis and treatment","volume":"27","author":"Behr","year":"2021","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S2213-2600(23)00259-X","article-title":"Pulmonary hypertension associated with lung disease: New insights into pathomechanisms, diagnosis, and management","volume":"11","author":"Olsson","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.amjmed.2015.11.026","article-title":"Pathophysiology of Pulmonary Hypertension in Chronic Parenchymal Lung Disease","volume":"129","author":"Singh","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/01.CIR.0000102381.57477.50","article-title":"Endothelial dysfunction in pulmonary hypertension","volume":"109","author":"Budhiraja","year":"2004","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"00503-2021","DOI":"10.1183\/23120541.00503-2021","article-title":"Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative computed tomography","volume":"8","author":"Alkhanfar","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2401095","DOI":"10.1183\/13993003.01095-2024","article-title":"Pathology and pathobiology of pulmonary hypertension: Current insights and future directions","volume":"64","author":"Guignabert","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/bph.15285","article-title":"Dysregulation of BMP9\/BMPR2\/SMAD signalling pathway contributes to pulmonary fibrosis and pulmonary hypertension induced by bleomycin in rats","volume":"178","author":"Jiang","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"L238","DOI":"10.1152\/ajplung.00142.2016","article-title":"Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension","volume":"311","author":"Chen","year":"2016","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.chest.2022.02.012","article-title":"Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study","volume":"162","author":"Rahaghi","year":"2022","journal-title":"Chest"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"210220","DOI":"10.1183\/16000617.0220-2021","article-title":"Recent advances in the management of pulmonary hypertension with interstitial lung disease","volume":"31","author":"Waxman","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"00659-2023","DOI":"10.1183\/23120541.00659-2023","article-title":"Severe pulmonary hypertension-interstitial lung disease presenting as right ventricular failure: Stabilisation with intravenous prostacyclin and maintenance with inhaled prostacyclin","volume":"10","author":"Parikh","year":"2024","journal-title":"ERJ Open Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.rmed.2008.11.012","article-title":"Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis","volume":"103","author":"Song","year":"2009","journal-title":"Respir. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1183\/09031936.00173509","article-title":"Elevated brain natriuretic peptide predicts mortality in interstitial lung disease","volume":"36","author":"Corte","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/art.1780350709","article-title":"Isolated diffusing capacity reduction in systemic sclerosis","volume":"35","author":"Steen","year":"1992","journal-title":"Arthritis Rheum."},{"key":"ref_46","first-page":"PA1333","article-title":"STARMAP: An observational study to assess disease-relevant outcomes using home-monitoring devices in patients with idiopathic pulmonary fibrosis (IPF)","volume":"54","author":"Swigris","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e12197","DOI":"10.1002\/pul2.12197","article-title":"Noninvasive determinants of pulmonary hypertension in interstitial lung disease","volume":"13","author":"Joseph","year":"2023","journal-title":"Pulm. Circ."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.chest.2020.04.046","article-title":"The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment","volume":"158","author":"King","year":"2020","journal-title":"Chest"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1164\/rccm.200811-1691OC","article-title":"Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension","volume":"179","author":"Fisher","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Arslan, A., Smith, J., Qureshi, M.R., Uysal, A., Patel, K.K., Herazo-Maya, J.D., and Bandyopadhyay, D. (2023). Evolution of pulmonary hypertension in interstitial lung disease: A journey through past, present, and future. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1306032"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.rmed.2007.05.012","article-title":"Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis","volume":"101","author":"Zisman","year":"2007","journal-title":"Respir. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1701311","DOI":"10.1183\/13993003.01311-2017","article-title":"A scoring system to predict the elevation of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis","volume":"51","author":"Furukawa","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"00124-2017","DOI":"10.1183\/23120541.00124-2017","article-title":"A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease","volume":"4","author":"Bax","year":"2018","journal-title":"ERJ Open Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/crj.13059","article-title":"Multimodal noninvasive prediction of pulmonary hypertension in IPF","volume":"13","author":"Sonti","year":"2019","journal-title":"Clin. Respir. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00408-020-00346-1","article-title":"Can a New Scoring System Improve Prediction of Pulmonary Hypertension in Newly Recognised Interstitial Lung Diseases?","volume":"198","author":"Sobiecka","year":"2020","journal-title":"Lung"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s11739-020-02539-1","article-title":"The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis","volume":"16","author":"Refini","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.healun.2023.11.005","article-title":"Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD","volume":"43","author":"Nathan","year":"2024","journal-title":"J. Heart Lung Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e12141","DOI":"10.1002\/pul2.12141","article-title":"Pulmonary hypertension in patients with interstitial lung disease: A tool for early detection","volume":"12","author":"Parikh","year":"2022","journal-title":"Pulm. Circ."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"240092","DOI":"10.1183\/16000617.0092-2024","article-title":"Noninvasive diagnostic modalities and prediction models for detecting pulmonary hypertension associated with interstitial lung disease: A narrative review","volume":"33","author":"Arvanitaki","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCRESAHA.121.319970","article-title":"Group 3 Pulmonary Hypertension: From Bench to Bedside","volume":"130","author":"Singh","year":"2022","journal-title":"Circ. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1164\/rccm.202212-2342CI","article-title":"Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease","volume":"208","author":"Nathan","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: A parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1183\/09031936.00104612","article-title":"Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial","volume":"42","author":"Raghu","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.201403-0446OC","article-title":"Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia","volume":"190","author":"Corte","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1755-5922.2011.00279.x","article-title":"ARIES-3: Ambrisentan therapy in a diverse population of patients with pulmonary hypertension","volume":"30","author":"Badesch","year":"2012","journal-title":"Cardiovasc. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1183\/09031936.00213911","article-title":"Riociguat for interstitial lung disease and pulmonary hypertension: A pilot trial","volume":"41","author":"Hoeper","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): A randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1440-1843.2010.01860.x","article-title":"The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease","volume":"15","author":"Corte","year":"2010","journal-title":"Respirology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/resp.12294","article-title":"Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors","volume":"19","author":"Zimmermann","year":"2014","journal-title":"Respirology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1378\/chest.06-2101","article-title":"Sildenafil improves walk distance in idiopathic pulmonary fibrosis","volume":"131","author":"Collard","year":"2007","journal-title":"Chest"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.vph.2009.04.002","article-title":"Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use?","volume":"51","author":"Chapman","year":"2009","journal-title":"Vascul Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1183\/13993003.02307-2014","article-title":"Severe pulmonary hypertension in lung disease: Phenotypes and response to treatment","volume":"46","author":"Brewis","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00408-009-9209-8","article-title":"Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis","volume":"188","author":"Jackson","year":"2010","journal-title":"Lung"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis","volume":"363","author":"Zisman","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/resp.14378","article-title":"Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study","volume":"28","author":"Dawes","year":"2023","journal-title":"Respirology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.160.2.9810008","article-title":"Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis","volume":"160","author":"Olschewski","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"633A","DOI":"10.1378\/chest.132.4_MeetingAbstracts.633a","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis","volume":"132","author":"Krowka","year":"2007","journal-title":"Chest"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.rmed.2008.02.002","article-title":"Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease","volume":"102","author":"Minai","year":"2008","journal-title":"Respir. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/thoraxjnl-2013-204150","article-title":"Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis","volume":"69","author":"Saggar","year":"2014","journal-title":"Thorax"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1164\/rccm.202107-1766OC","article-title":"Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial","volume":"205","author":"Nathan","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: A post-hoc analysis of the INCREASE study","volume":"9","author":"Nathan","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1513\/AnnalsATS.202303-229RL","article-title":"A Novel Approach to Clinical Change Endpoints: A Win Ratio Analysis of the INCREASE Trial","volume":"20","author":"Nathan","year":"2023","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_87","first-page":"301","article-title":"Survival analysis from the INCREASE study in PH-ILD: Evaluating the impact of treatment crossover on overall mortality","volume":"79","author":"Nathan","year":"2024","journal-title":"Thorax"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.resinv.2024.07.020","article-title":"Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease","volume":"62","author":"Sakao","year":"2024","journal-title":"Respir. Investig."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e12178","DOI":"10.1002\/pul2.12178","article-title":"Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute\u2019s Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension","volume":"12","author":"Nathan","year":"2022","journal-title":"Pulm. Circ."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/2029\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:54:53Z","timestamp":1760028893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/2029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":89,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14062029"],"URL":"https:\/\/doi.org\/10.3390\/jcm14062029","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]}}}